Trastuzumab emtansine: Indication of major added benefit in one subpopulation
The antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast cancer that is HER2-positive, ...
Apr 7, 2014